The Department of Health – Abu Dhabi (DoH) has signed a Memorandum of Understanding with AbbVie Biopharmaceutical and M42 to advance personalised medicine and genomics in Abu Dhabi. The three parties aim to advance precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer. This strategic cooperation aims to maximise on the Emirate's unique genomics programme and translate scientific advancements into tangible patient benefits, focusing on precision medicine tailored to individual needs.
Abu Dhabi launched the region's first Personalised Precision Medicine Programme for oncology in 2022 as part of its preventive healthcare efforts. DoH seeks to drive research that will contribute to policy changes and guideline implementation which will enable broader patient access to innovative approaches in healthcare.
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi (DoH), said: "It is with no doubt that personalised medicine and genomics hold the transformative potential to reshape the delivery of care and improve outcomes."
Keywords: Department, Abu Dhabi, personalized medicine, genomics